Ovid Therapeutics Inc.
Ovid Therapeutics Inc. (OVID) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · OVID · as of Sep 30, 2025
Ownership Breakdown
84
Institutional Holders
▲ 13 vs Q2
$47.08M
Total Inst. Value
▲ $35.21M vs Q2
131.88M
Shares Outstanding
freeFloat 86.41%
36.21M
13F Shares Held
▲ 247,519 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
OVID largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
TAKEDA PHARMACEUTICAL CO LTD pharmaceutical preparations | 7.53M | 10.59% | 10.59% | $9.79B | Nov 13, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 2.82M | 3.97% | 3.97% | $3.67B | Nov 7, 2025 | ▲ 184.7K |
AFFINITY ASSET ADVISORS, LLC pharmaceutical preparations | 2.65M | 3.73% | 3.73% | $3.44B | Nov 13, 2025 | ▲ 1.98M |
ACADIAN ASSET MANAGEMENT LLC pharmaceutical preparations | 2.29M | 3.22% | 3.22% | $2.97B | Nov 13, 2025 | ▲ 178.2K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 2.02M | 2.84% | 2.84% | $2.62B | Nov 13, 2025 | ▼ 77.3K |
SIO CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 1.43M | 2.01% | 2.01% | $1.86B | Nov 13, 2025 | ▼ 804.5K |
DRIEHAUS CAPITAL MANAGEMENT LLC pharmaceutical preparations | 1.40M | 1.97% | 1.97% | $1.82B | Nov 14, 2025 | — held |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 1.35M | 1.90% | 1.90% | $1.75B | Nov 14, 2025 | ▲ 200.0K |
KENNEDY CAPITAL MANAGEMENT LLC pharmaceutical preparations | 1.11M | 1.56% | 1.56% | $1.44B | Nov 13, 2025 | ▼ 395.7K |
IKARIAN CAPITAL, LLC pharmaceutical preparations | 1.10M | 1.54% | 1.54% | $1.42B | Nov 14, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
18
Increased
+5.45M shares15
New Positions
first time holders10
Decreased
−2.97M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.48M
+5.45M / −2.97M
Net new holders
+23
15 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
OVID insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
PAPADOPOULOS STELIOS director | Apr 7, 2026 | Award | 17,578 | $2.56 | $45.0K | 217.6K | Form 4 ↗ |
Friedman Bart director | Apr 7, 2026 | Award | 8,789 | $2.56 | $22.5K | 8.8K | Form 4 ↗ |
Fitzgerald Kevin Joseph director | Apr 7, 2026 | Award | 17,578 | $2.56 | $45.0K | 17.6K | Form 4 ↗ |
ALEXANDER MARGARET A. President and CEO | Feb 26, 2026 | Award | 1,435,000 | $1.65 | $2.37M | 1.44M | Form 4 ↗ |
ALEXANDER MARGARET A. President and CEO | Feb 23, 2026 | Sale | 11,656 | $1.45 | $16.9K | 61.8K | Form 4 ↗ |
PAPADOPOULOS STELIOS director | Feb 26, 2026 | Award | 65,000 | $1.65 | $107.3K | 65.0K | Form 4 ↗ |
LEVIN JEREMY M director | Feb 26, 2026 | Award | 957,000 | $1.65 | $1.58M | 957.0K | Form 4 ↗ |
Fitzgerald Kevin Joseph director | Feb 26, 2026 | Award | 65,000 | $1.65 | $107.3K | 65.0K | Form 4 ↗ |
Friedman Bart director | Feb 26, 2026 | Award | 65,000 | $1.65 | $107.3K | 65.0K | Form 4 ↗ |
DUNCAN BARBARA GAYLE director | Feb 26, 2026 | Award | 65,000 | $1.65 | $107.3K | 65.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Ovid Therapeutics Inc. (OVID) is primarily owned by institutional investors, who hold approximately 27.5% of total shares outstanding. Company insiders own approximately 13.59%, while retail and public investors account for the remaining 58.95%.
The largest institutional shareholder of Ovid Therapeutics Inc. is TAKEDA PHARMACEUTICAL CO LTD, holding approximately 7.53 million shares — equal to 10.59% of outstanding shares — as of September 30, 2025.
A total of 84 institutional investors currently hold OVID stock, with a combined institutional value of approximately $47,075,130 as of the most recent 13F filing period.
Frequently asked questions
OVID ownershipOvid Therapeutics Inc. (OVID) is primarily owned by institutional investors, who hold approximately 27.5% of shares. The largest shareholder is TAKEDA PHARMACEUTICAL CO LTD with a 10.59% stake. Company insiders hold 13.59%. Data sourced from SEC Form 13F as of September 30, 2025.